Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan ; volume:150 ; number:4 ; day:9 ; month:4 ; year:2024 ; pages:1-9 ; date:4.2024
Journal of cancer research and clinical oncology ; 150, Heft 4 (9.4.2024), 1-9, 4.2024
- Urheber
-
Hirasawa, Yosuke
Adachi, Takahiro
Hashimoto, Takeshi
Fukuokaya, Wataru
Koike, Yuhei
Yata, Yuji
Komura, Kazumasa
Uchimoto, Taizo
Tsujino, Takuya
Nishimura, Kazuki
Takahara, Kiyoshi
Saruta, Masanobu
Fujita, Kazutoshi
Hashimoto, Mamoru
Uemura, Hirotsugu
Shiroki, Ryoichi
Azuma, Takashi
Kimura, Takahiro
Ohno, Yoshio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-024-05717-2
- URN
-
urn:nbn:de:101:1-2408020909057.099835734277
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hirasawa, Yosuke
- Adachi, Takahiro
- Hashimoto, Takeshi
- Fukuokaya, Wataru
- Koike, Yuhei
- Yata, Yuji
- Komura, Kazumasa
- Uchimoto, Taizo
- Tsujino, Takuya
- Nishimura, Kazuki
- Takahara, Kiyoshi
- Saruta, Masanobu
- Fujita, Kazutoshi
- Hashimoto, Mamoru
- Uemura, Hirotsugu
- Shiroki, Ryoichi
- Azuma, Takashi
- Kimura, Takahiro
- Ohno, Yoshio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Pembrolizumab (Urothelkarzinom, Erstlinientherapie, Kombination mit Enfortumab Vedotin) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Pembrolizumab (Urothelkarzinom, Erstlinientherapie, Kombination mit Enfortumab Vedotin) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Pembrolizumab (Urothelkarzinom, Erstlinientherapie, Kombination mit Enfortumab Vedotin) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study
Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies